 Robert Fuhlbrigge
Concepts (494)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin | 22 | 2017 | 662 | 2.640 |
Why?
| | Arthritis, Juvenile | 9 | 2022 | 42 | 1.910 |
Why?
| | Vaccinia virus | 7 | 2017 | 28 | 1.440 |
Why?
| | Rheumatic Diseases | 3 | 2021 | 49 | 1.260 |
Why?
| | E-Selectin | 15 | 2019 | 54 | 1.250 |
Why?
| | Vaccinia | 4 | 2017 | 18 | 1.050 |
Why?
| | Membrane Glycoproteins | 13 | 2007 | 431 | 0.880 |
Why?
| | CD8-Positive T-Lymphocytes | 7 | 2021 | 693 | 0.860 |
Why?
| | Cell Adhesion | 14 | 2015 | 433 | 0.820 |
Why?
| | Blotting, Western | 7 | 2015 | 1153 | 0.790 |
Why?
| | Immunologic Surveillance | 4 | 2011 | 19 | 0.780 |
Why?
| | T-Lymphocytes | 12 | 2019 | 1756 | 0.740 |
Why?
| | Rheumatology | 1 | 2021 | 89 | 0.710 |
Why?
| | Down Syndrome | 2 | 2021 | 336 | 0.680 |
Why?
| | Selectins | 5 | 2015 | 7 | 0.670 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 376 | 0.630 |
Why?
| | Skin Diseases | 3 | 2009 | 124 | 0.630 |
Why?
| | Immune System | 3 | 2011 | 173 | 0.620 |
Why?
| | Hemorrhage | 2 | 2023 | 618 | 0.610 |
Why?
| | Scleroderma, Localized | 4 | 2024 | 7 | 0.610 |
Why?
| | Skin Diseases, Infectious | 1 | 2017 | 16 | 0.580 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2020 | 342 | 0.570 |
Why?
| | Receptors, Lymphocyte Homing | 5 | 2007 | 15 | 0.550 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2017 | 254 | 0.550 |
Why?
| | Cell Adhesion Molecules | 3 | 2007 | 168 | 0.540 |
Why?
| | Antirheumatic Agents | 4 | 2022 | 255 | 0.530 |
Why?
| | Cell Movement | 16 | 2017 | 867 | 0.500 |
Why?
| | Leukocytes | 6 | 2006 | 281 | 0.490 |
Why?
| | Lung Diseases | 1 | 2021 | 710 | 0.490 |
Why?
| | Interleukin-1alpha | 2 | 2020 | 55 | 0.480 |
Why?
| | Intercellular Adhesion Molecule-1 | 4 | 2019 | 155 | 0.470 |
Why?
| | Immunologic Memory | 7 | 2024 | 314 | 0.470 |
Why?
| | Mechanical Phenomena | 1 | 2015 | 83 | 0.460 |
Why?
| | Dendritic Cells | 8 | 2016 | 438 | 0.440 |
Why?
| | P-Selectin | 10 | 2012 | 25 | 0.410 |
Why?
| | Antibodies, Monoclonal | 12 | 2020 | 1265 | 0.410 |
Why?
| | Scleroderma, Systemic | 3 | 2024 | 95 | 0.400 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 73 | 0.400 |
Why?
| | Animals | 45 | 2024 | 32102 | 0.400 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 5 | 2012 | 40 | 0.390 |
Why?
| | Models, Immunological | 4 | 2012 | 92 | 0.370 |
Why?
| | Child | 28 | 2024 | 18488 | 0.370 |
Why?
| | T-Lymphocyte Subsets | 5 | 2017 | 383 | 0.370 |
Why?
| | Leukosialin | 3 | 2011 | 15 | 0.360 |
Why?
| | L-Selectin | 7 | 2000 | 25 | 0.350 |
Why?
| | Systemic Vasculitis | 1 | 2009 | 2 | 0.350 |
Why?
| | Mice, Knockout | 11 | 2021 | 2604 | 0.320 |
Why?
| | Th17 Cells | 2 | 2020 | 59 | 0.320 |
Why?
| | Mice | 30 | 2021 | 15052 | 0.320 |
Why?
| | Humans | 73 | 2024 | 115587 | 0.320 |
Why?
| | Antigens, Neoplasm | 9 | 2007 | 223 | 0.320 |
Why?
| | Antibodies, Viral | 1 | 2012 | 527 | 0.310 |
Why?
| | Skin Neoplasms | 4 | 2012 | 761 | 0.310 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2015 | 156 | 0.300 |
Why?
| | Cricetinae | 8 | 2015 | 260 | 0.300 |
Why?
| | Blood Vessels | 1 | 2009 | 181 | 0.300 |
Why?
| | Comparative Effectiveness Research | 2 | 2019 | 130 | 0.300 |
Why?
| | Mice, Inbred C57BL | 15 | 2020 | 4773 | 0.300 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 111 | 0.300 |
Why?
| | Melanoma | 3 | 2012 | 651 | 0.290 |
Why?
| | Immunity, Innate | 5 | 2012 | 731 | 0.290 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2012 | 1137 | 0.290 |
Why?
| | CHO Cells | 6 | 2015 | 140 | 0.280 |
Why?
| | Chemokines, CC | 3 | 2004 | 28 | 0.280 |
Why?
| | Lymphocyte Activation | 4 | 2010 | 1057 | 0.260 |
Why?
| | Monocytes | 3 | 2005 | 507 | 0.250 |
Why?
| | Biological Assay | 1 | 2006 | 114 | 0.250 |
Why?
| | Chemotaxis, Leukocyte | 4 | 2013 | 130 | 0.250 |
Why?
| | Synovial Membrane | 2 | 2024 | 75 | 0.250 |
Why?
| | Arthritis, Rheumatoid | 2 | 2024 | 1002 | 0.240 |
Why?
| | Methotrexate | 4 | 2019 | 228 | 0.230 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 8 | 2007 | 85 | 0.230 |
Why?
| | Microscopic Polyangiitis | 1 | 2023 | 12 | 0.230 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2023 | 20 | 0.220 |
Why?
| | Churg-Strauss Syndrome | 1 | 2023 | 17 | 0.220 |
Why?
| | Glucocorticoids | 3 | 2019 | 552 | 0.220 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2023 | 41 | 0.220 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2020 | 193 | 0.220 |
Why?
| | Myositis | 1 | 2023 | 44 | 0.210 |
Why?
| | Thymus Gland | 1 | 2004 | 299 | 0.210 |
Why?
| | Granuloma | 1 | 2023 | 85 | 0.210 |
Why?
| | Cricetulus | 3 | 2015 | 99 | 0.210 |
Why?
| | Spondylarthropathies | 1 | 2022 | 6 | 0.210 |
Why?
| | Consensus | 4 | 2024 | 532 | 0.200 |
Why?
| | Keratinocytes | 3 | 2016 | 215 | 0.200 |
Why?
| | Interleukin-1 | 5 | 1989 | 971 | 0.200 |
Why?
| | Adolescent | 15 | 2024 | 17889 | 0.200 |
Why?
| | Spondylarthritis | 1 | 2022 | 36 | 0.200 |
Why?
| | Adaptive Immunity | 2 | 2020 | 157 | 0.190 |
Why?
| | Spondylitis, Ankylosing | 1 | 2022 | 43 | 0.190 |
Why?
| | Sarcoidosis | 1 | 2023 | 134 | 0.190 |
Why?
| | Gene Expression Regulation | 3 | 2015 | 2353 | 0.190 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 221 | 0.190 |
Why?
| | Endothelium, Vascular | 5 | 2019 | 845 | 0.180 |
Why?
| | Severity of Illness Index | 3 | 2024 | 2578 | 0.180 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2016 | 965 | 0.180 |
Why?
| | Immunization | 2 | 2016 | 401 | 0.180 |
Why?
| | Melanoma, Experimental | 2 | 2019 | 118 | 0.180 |
Why?
| | Immunomodulation | 1 | 2020 | 85 | 0.180 |
Why?
| | Child, Preschool | 12 | 2021 | 9133 | 0.170 |
Why?
| | Female | 29 | 2024 | 59913 | 0.170 |
Why?
| | Neoplasm Proteins | 3 | 2017 | 385 | 0.170 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 279 | 0.170 |
Why?
| | Cellular Reprogramming | 1 | 2020 | 84 | 0.170 |
Why?
| | Advisory Committees | 1 | 2020 | 208 | 0.170 |
Why?
| | Keratin-14 | 2 | 2009 | 12 | 0.160 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 249 | 0.160 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 3 | 2012 | 76 | 0.160 |
Why?
| | Immunoglobulin G | 2 | 2012 | 781 | 0.150 |
Why?
| | Ligands | 10 | 2016 | 569 | 0.150 |
Why?
| | Cell Polarity | 2 | 2016 | 131 | 0.150 |
Why?
| | Interleukin-1beta | 1 | 2020 | 370 | 0.150 |
Why?
| | Candidiasis | 1 | 2017 | 58 | 0.150 |
Why?
| | Candida albicans | 1 | 2017 | 55 | 0.150 |
Why?
| | Kaposi Varicelliform Eruption | 1 | 2017 | 24 | 0.140 |
Why?
| | Lymphadenitis | 1 | 2016 | 4 | 0.140 |
Why?
| | Hereditary Autoinflammatory Diseases | 1 | 2016 | 6 | 0.140 |
Why?
| | Administration, Cutaneous | 1 | 2017 | 116 | 0.140 |
Why?
| | Cells, Cultured | 13 | 2017 | 3914 | 0.140 |
Why?
| | Stomatitis, Aphthous | 1 | 2016 | 10 | 0.140 |
Why?
| | Pharyngitis | 1 | 2016 | 23 | 0.140 |
Why?
| | Clinical Protocols | 1 | 2018 | 234 | 0.140 |
Why?
| | Interleukin-23 | 1 | 2016 | 15 | 0.140 |
Why?
| | Dermatomyositis | 2 | 2009 | 23 | 0.140 |
Why?
| | Receptors, CCR4 | 3 | 2012 | 15 | 0.140 |
Why?
| | Virus Replication | 2 | 2017 | 396 | 0.130 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2017 | 151 | 0.130 |
Why?
| | Transcriptome | 1 | 2021 | 736 | 0.130 |
Why?
| | Psoriasis | 3 | 2017 | 75 | 0.130 |
Why?
| | Neoplasms | 3 | 2020 | 2118 | 0.130 |
Why?
| | Immune Tolerance | 2 | 2009 | 332 | 0.130 |
Why?
| | Male | 21 | 2024 | 55949 | 0.130 |
Why?
| | Interleukins | 2 | 2016 | 238 | 0.130 |
Why?
| | Neutrophils | 4 | 2012 | 1172 | 0.130 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2015 | 11 | 0.120 |
Why?
| | Mice, SCID | 4 | 2020 | 321 | 0.120 |
Why?
| | Granzymes | 1 | 2015 | 40 | 0.120 |
Why?
| | Dermatitis, Atopic | 2 | 2009 | 310 | 0.120 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 66 | 0.120 |
Why?
| | Young Adult | 5 | 2023 | 10470 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2010 | 630 | 0.120 |
Why?
| | Interleukin-17 | 2 | 2017 | 106 | 0.120 |
Why?
| | Hyaluronan Receptors | 3 | 2011 | 91 | 0.120 |
Why?
| | Hematopoietic Stem Cells | 2 | 2011 | 346 | 0.120 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2015 | 69 | 0.120 |
Why?
| | Lipid Metabolism | 1 | 2017 | 449 | 0.110 |
Why?
| | Toll-Like Receptor 4 | 1 | 2016 | 285 | 0.110 |
Why?
| | HLA-DR Antigens | 1 | 2015 | 221 | 0.110 |
Why?
| | Dermatitis, Allergic Contact | 2 | 2011 | 63 | 0.110 |
Why?
| | Receptors, CCR7 | 1 | 2013 | 24 | 0.110 |
Why?
| | Microscopy | 1 | 2015 | 125 | 0.110 |
Why?
| | B-Lymphocytes | 4 | 2011 | 773 | 0.110 |
Why?
| | Biomechanical Phenomena | 2 | 2015 | 677 | 0.110 |
Why?
| | Cell Line | 5 | 2011 | 2651 | 0.110 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2012 | 19 | 0.110 |
Why?
| | Interleukin-9 | 1 | 2012 | 10 | 0.100 |
Why?
| | CD18 Antigens | 1 | 2012 | 33 | 0.100 |
Why?
| | Antigens, Ly | 1 | 2012 | 45 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2018 | 1216 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2016 | 341 | 0.100 |
Why?
| | Autoimmune Diseases | 2 | 2007 | 395 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2012 | 95 | 0.100 |
Why?
| | Lymphocyte Count | 1 | 2012 | 133 | 0.100 |
Why?
| | Interferon-gamma | 2 | 2012 | 726 | 0.100 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 235 | 0.100 |
Why?
| | Transforming Growth Factors | 1 | 2011 | 3 | 0.100 |
Why?
| | Inflammation | 6 | 2012 | 2499 | 0.100 |
Why?
| | Langerhans Cells | 1 | 2011 | 11 | 0.100 |
Why?
| | Vaccination | 2 | 2017 | 1209 | 0.100 |
Why?
| | Antigens, CD34 | 1 | 2011 | 90 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2015 | 677 | 0.090 |
Why?
| | Antigens, CD | 2 | 2007 | 442 | 0.090 |
Why?
| | Epidermis | 2 | 2016 | 149 | 0.090 |
Why?
| | Biomarkers | 3 | 2023 | 3466 | 0.090 |
Why?
| | Prospective Studies | 4 | 2024 | 6264 | 0.090 |
Why?
| | Program Development | 1 | 2012 | 350 | 0.090 |
Why?
| | Viral Load | 1 | 2012 | 405 | 0.090 |
Why?
| | Integrins | 1 | 2010 | 79 | 0.090 |
Why?
| | Fucosyltransferases | 3 | 2018 | 28 | 0.090 |
Why?
| | Mice, Inbred BALB C | 4 | 2018 | 1168 | 0.090 |
Why?
| | Flow Cytometry | 6 | 2013 | 1083 | 0.090 |
Why?
| | Cytokines | 3 | 2007 | 1853 | 0.080 |
Why?
| | beta Catenin | 1 | 2011 | 220 | 0.080 |
Why?
| | Metalloendopeptidases | 4 | 2012 | 55 | 0.080 |
Why?
| | Microtubule-Associated Proteins | 1 | 2010 | 174 | 0.080 |
Why?
| | Lymph Nodes | 4 | 2016 | 423 | 0.080 |
Why?
| | Hypersensitivity, Delayed | 2 | 2007 | 52 | 0.080 |
Why?
| | Receptors, Interleukin-1 | 2 | 2006 | 227 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2024 | 741 | 0.080 |
Why?
| | Shear Strength | 1 | 2009 | 55 | 0.080 |
Why?
| | Ovalbumin | 1 | 2009 | 166 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2009 | 1970 | 0.080 |
Why?
| | Joints | 2 | 2024 | 84 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2020 | 2751 | 0.080 |
Why?
| | Toll-Like Receptors | 1 | 2009 | 166 | 0.080 |
Why?
| | Rheology | 1 | 2009 | 88 | 0.080 |
Why?
| | Arthritis | 2 | 2024 | 111 | 0.080 |
Why?
| | Cancer Vaccines | 2 | 2012 | 137 | 0.080 |
Why?
| | Vitamin A | 1 | 2007 | 52 | 0.070 |
Why?
| | Self Tolerance | 1 | 2007 | 28 | 0.070 |
Why?
| | MART-1 Antigen | 1 | 2007 | 10 | 0.070 |
Why?
| | Toll-Like Receptor 7 | 1 | 2007 | 35 | 0.070 |
Why?
| | Cholecalciferol | 1 | 2007 | 47 | 0.070 |
Why?
| | Killer Cells, Natural | 2 | 2007 | 383 | 0.070 |
Why?
| | Chemokine CCL17 | 2 | 2004 | 4 | 0.070 |
Why?
| | Drug Therapy, Combination | 3 | 2019 | 962 | 0.070 |
Why?
| | CD8 Antigens | 1 | 2007 | 69 | 0.070 |
Why?
| | Receptors, Chemokine | 2 | 2006 | 43 | 0.070 |
Why?
| | Microcirculation | 2 | 2005 | 138 | 0.070 |
Why?
| | HeLa Cells | 1 | 2008 | 567 | 0.070 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2007 | 174 | 0.070 |
Why?
| | Polysaccharides | 3 | 2011 | 80 | 0.070 |
Why?
| | Th1 Cells | 1 | 2007 | 125 | 0.070 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 3 | 2010 | 36 | 0.070 |
Why?
| | Up-Regulation | 2 | 2009 | 820 | 0.070 |
Why?
| | Vitamin D | 1 | 2009 | 341 | 0.070 |
Why?
| | Sialoglycoproteins | 1 | 2006 | 158 | 0.070 |
Why?
| | Methylprednisolone | 2 | 2019 | 83 | 0.070 |
Why?
| | Cell Lineage | 1 | 2008 | 310 | 0.070 |
Why?
| | Microscopy, Video | 1 | 2006 | 26 | 0.070 |
Why?
| | Neuraminidase | 4 | 2001 | 22 | 0.070 |
Why?
| | Urticaria | 1 | 2006 | 51 | 0.070 |
Why?
| | Wiskott-Aldrich Syndrome Protein | 1 | 2005 | 2 | 0.070 |
Why?
| | Viral Vaccines | 1 | 2006 | 90 | 0.060 |
Why?
| | Bone Marrow Cells | 3 | 2002 | 268 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1000 | 0.060 |
Why?
| | Disease Progression | 3 | 2024 | 2418 | 0.060 |
Why?
| | Graft vs Host Disease | 1 | 2007 | 212 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 666 | 0.060 |
Why?
| | Membrane Proteins | 3 | 1998 | 1024 | 0.060 |
Why?
| | Immunologic Factors | 1 | 2007 | 220 | 0.060 |
Why?
| | Carrier Proteins | 2 | 2006 | 701 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1405 | 0.060 |
Why?
| | Neoplastic Stem Cells | 1 | 2008 | 331 | 0.060 |
Why?
| | Th2 Cells | 1 | 2005 | 157 | 0.060 |
Why?
| | Neutrophil Activation | 2 | 2012 | 94 | 0.060 |
Why?
| | Smallpox Vaccine | 1 | 2004 | 22 | 0.060 |
Why?
| | Monitoring, Immunologic | 1 | 2004 | 23 | 0.060 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2004 | 57 | 0.060 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2003 | 12 | 0.060 |
Why?
| | Leukocytosis | 1 | 2003 | 35 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 1987 | 826 | 0.060 |
Why?
| | Cell Separation | 3 | 2013 | 293 | 0.060 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2023 | 33 | 0.060 |
Why?
| | Raynaud Disease | 1 | 2003 | 5 | 0.060 |
Why?
| | Fasciitis | 1 | 2023 | 10 | 0.060 |
Why?
| | Coronary Vessels | 1 | 2005 | 229 | 0.050 |
Why?
| | Observer Variation | 1 | 2024 | 297 | 0.050 |
Why?
| | Mice, Inbred NOD | 2 | 2019 | 560 | 0.050 |
Why?
| | Neutropenia | 1 | 2003 | 127 | 0.050 |
Why?
| | Immunocompetence | 2 | 2017 | 41 | 0.050 |
Why?
| | Adult | 7 | 2022 | 30718 | 0.050 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2003 | 120 | 0.050 |
Why?
| | Prednisone | 2 | 2019 | 232 | 0.050 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 402 | 0.050 |
Why?
| | Chemokines, CXC | 2 | 2005 | 58 | 0.050 |
Why?
| | Registries | 2 | 2020 | 1770 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 3 | 2012 | 616 | 0.050 |
Why?
| | Syndrome | 2 | 2016 | 339 | 0.050 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2006 | 691 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2020 | 3580 | 0.050 |
Why?
| | Hemorheology | 2 | 1999 | 20 | 0.050 |
Why?
| | Acute Disease | 2 | 2020 | 914 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1646 | 0.050 |
Why?
| | B-Lymphocyte Subsets | 1 | 2001 | 68 | 0.050 |
Why?
| | Fibrosis | 1 | 2023 | 457 | 0.050 |
Why?
| | Immunoblotting | 2 | 1998 | 281 | 0.040 |
Why?
| | Macrophages | 1 | 1987 | 1284 | 0.040 |
Why?
| | Calcinosis | 1 | 2002 | 242 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 75 | 0.040 |
Why?
| | Glycosylation | 2 | 2012 | 133 | 0.040 |
Why?
| | Cell Differentiation | 3 | 2017 | 1700 | 0.040 |
Why?
| | Lower Extremity | 1 | 2023 | 337 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1642 | 0.040 |
Why?
| | Protein Binding | 3 | 2012 | 1917 | 0.040 |
Why?
| | Immunophenotyping | 2 | 2015 | 277 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 5077 | 0.040 |
Why?
| | Remission Induction | 2 | 2010 | 240 | 0.040 |
Why?
| | Integrin beta Chains | 1 | 2018 | 6 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 126 | 0.040 |
Why?
| | Calcium | 2 | 2012 | 1103 | 0.040 |
Why?
| | Rare Diseases | 1 | 2019 | 89 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 318 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 193 | 0.040 |
Why?
| | Signal Transduction | 4 | 2015 | 4541 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2020 | 258 | 0.040 |
Why?
| | Interleukin-2 | 2 | 2010 | 417 | 0.040 |
Why?
| | Epitopes | 2 | 1998 | 438 | 0.040 |
Why?
| | Endothelium, Lymphatic | 1 | 1998 | 12 | 0.040 |
Why?
| | Allografts | 1 | 2018 | 127 | 0.040 |
Why?
| | Culture Media, Serum-Free | 1 | 1997 | 42 | 0.040 |
Why?
| | Oligosaccharides | 1 | 1998 | 47 | 0.040 |
Why?
| | Altitude | 1 | 2021 | 409 | 0.040 |
Why?
| | Down-Regulation | 2 | 2012 | 601 | 0.040 |
Why?
| | Pain | 1 | 2023 | 712 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 431 | 0.040 |
Why?
| | Familial Mediterranean Fever | 1 | 2016 | 6 | 0.040 |
Why?
| | Turkey | 1 | 2016 | 14 | 0.040 |
Why?
| | Administration, Oral | 1 | 2019 | 734 | 0.040 |
Why?
| | Hospitals | 1 | 2021 | 585 | 0.040 |
Why?
| | Edetic Acid | 1 | 1996 | 44 | 0.040 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 1996 | 64 | 0.040 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2017 | 63 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2015 | 3022 | 0.030 |
Why?
| | Boston | 1 | 2016 | 74 | 0.030 |
Why?
| | Chelating Agents | 1 | 1996 | 71 | 0.030 |
Why?
| | Endopeptidases | 1 | 1996 | 72 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 1856 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 1997 | 170 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2024 | 2800 | 0.030 |
Why?
| | Infant | 4 | 2012 | 7979 | 0.030 |
Why?
| | Antibodies | 2 | 2012 | 374 | 0.030 |
Why?
| | Synovial Fluid | 1 | 2016 | 57 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 836 | 0.030 |
Why?
| | Lymphocytes | 1 | 1998 | 344 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2017 | 309 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 375 | 0.030 |
Why?
| | Eosinophils | 1 | 1997 | 282 | 0.030 |
Why?
| | Hematopoiesis | 1 | 2016 | 173 | 0.030 |
Why?
| | Chemokines | 1 | 1996 | 214 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 1997 | 401 | 0.030 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2007 | 80 | 0.030 |
Why?
| | Dermatitis, Contact | 2 | 2007 | 24 | 0.030 |
Why?
| | Glycolipids | 1 | 1995 | 37 | 0.030 |
Why?
| | Antigens | 1 | 2016 | 323 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1377 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2012 | 2790 | 0.030 |
Why?
| | Rituximab | 2 | 2007 | 149 | 0.030 |
Why?
| | Treatment Outcome | 4 | 2012 | 9159 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2015 | 149 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2017 | 924 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1024 | 0.030 |
Why?
| | Global Health | 1 | 2016 | 290 | 0.030 |
Why?
| | Contractile Proteins | 1 | 2012 | 16 | 0.030 |
Why?
| | Quality Improvement | 1 | 2020 | 958 | 0.030 |
Why?
| | Middle Aged | 3 | 2023 | 26999 | 0.030 |
Why?
| | Filamins | 1 | 2012 | 19 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 1893 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2021 | 12608 | 0.030 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 11 | 0.030 |
Why?
| | Radiation Chimera | 1 | 2012 | 31 | 0.030 |
Why?
| | Receptors, Leukotriene B4 | 1 | 2012 | 8 | 0.030 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2012 | 13 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2012 | 48 | 0.030 |
Why?
| | Receptors, Interleukin | 1 | 2012 | 39 | 0.030 |
Why?
| | Peritoneum | 1 | 2012 | 36 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1334 | 0.030 |
Why?
| | Mice, Inbred CBA | 2 | 1989 | 56 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2012 | 96 | 0.030 |
Why?
| | Biomedical Research | 1 | 2018 | 588 | 0.030 |
Why?
| | Lymphoid Tissue | 2 | 2005 | 63 | 0.030 |
Why?
| | Local Lymph Node Assay | 1 | 2011 | 1 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2012 | 126 | 0.020 |
Why?
| | Chemotaxis | 1 | 2012 | 132 | 0.020 |
Why?
| | Genetic Variation | 1 | 2016 | 877 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2987 | 0.020 |
Why?
| | Mast Cells | 1 | 2012 | 117 | 0.020 |
Why?
| | Chemokine CXCL12 | 2 | 2005 | 74 | 0.020 |
Why?
| | Longitudinal Studies | 2 | 2009 | 2416 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 276 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 261 | 0.020 |
Why?
| | Cloning, Molecular | 1 | 2012 | 523 | 0.020 |
Why?
| | Natural Killer T-Cells | 1 | 2011 | 63 | 0.020 |
Why?
| | Motor Activity | 1 | 2016 | 633 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4113 | 0.020 |
Why?
| | Risk Factors | 2 | 2016 | 8697 | 0.020 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2010 | 41 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 2012 | 194 | 0.020 |
Why?
| | Aged | 2 | 2023 | 19251 | 0.020 |
Why?
| | Blood Circulation | 1 | 2010 | 35 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2011 | 204 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2005 | 1357 | 0.020 |
Why?
| | Diphtheria Toxin | 1 | 2010 | 51 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 5548 | 0.020 |
Why?
| | Incidence | 1 | 2016 | 2335 | 0.020 |
Why?
| | Complement System Proteins | 1 | 2012 | 288 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2012 | 645 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2009 | 4440 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 2194 | 0.020 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1989 | 54 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 544 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 1988 | 36 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 1 | 1988 | 49 | 0.020 |
Why?
| | Precipitin Tests | 1 | 1988 | 90 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 2829 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 1989 | 153 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2012 | 465 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2010 | 186 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2001 | 312 | 0.020 |
Why?
| | Muscle Weakness | 1 | 2009 | 80 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2012 | 2000 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2009 | 123 | 0.020 |
Why?
| | Stress, Mechanical | 2 | 2001 | 440 | 0.020 |
Why?
| | Tissue Array Analysis | 1 | 2008 | 49 | 0.020 |
Why?
| | Allergens | 1 | 2011 | 418 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1989 | 203 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 1987 | 23 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2008 | 187 | 0.020 |
Why?
| | Cell Compartmentation | 1 | 1987 | 52 | 0.020 |
Why?
| | Umbilical Veins | 2 | 1997 | 58 | 0.020 |
Why?
| | Receptors, CCR6 | 1 | 2006 | 3 | 0.020 |
Why?
| | Proteomics | 1 | 2012 | 859 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2007 | 147 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 1 | 2006 | 65 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2010 | 1178 | 0.020 |
Why?
| | CD4 Antigens | 1 | 2006 | 124 | 0.020 |
Why?
| | Macrophage Activation | 1 | 1987 | 165 | 0.020 |
Why?
| | Mice, Nude | 1 | 2008 | 639 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 374 | 0.020 |
Why?
| | Papilledema | 1 | 2006 | 38 | 0.020 |
Why?
| | Vaccines, Attenuated | 1 | 2006 | 113 | 0.020 |
Why?
| | Genetic Linkage | 1 | 1987 | 297 | 0.020 |
Why?
| | Cell Division | 1 | 2008 | 759 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4435 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1536 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2006 | 177 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 171 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2007 | 1870 | 0.020 |
Why?
| | Dilatation, Pathologic | 1 | 2005 | 54 | 0.020 |
Why?
| | United States | 1 | 2021 | 12295 | 0.020 |
Why?
| | Receptors, CXCR4 | 1 | 2005 | 78 | 0.020 |
Why?
| | Meningitis | 1 | 2006 | 74 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1988 | 1243 | 0.020 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2006 | 145 | 0.020 |
Why?
| | Intellectual Disability | 1 | 2006 | 129 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 724 | 0.020 |
Why?
| | Fibronectins | 1 | 2005 | 108 | 0.020 |
Why?
| | Biological Evolution | 1 | 1989 | 417 | 0.020 |
Why?
| | Cytoskeletal Proteins | 1 | 2005 | 145 | 0.020 |
Why?
| | Interferon Type I | 1 | 1985 | 129 | 0.010 |
Why?
| | Kinetics | 2 | 1998 | 1569 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2005 | 177 | 0.010 |
Why?
| | Fever | 1 | 2005 | 280 | 0.010 |
Why?
| | Bronchitis | 1 | 2003 | 37 | 0.010 |
Why?
| | Cell Membrane | 1 | 1987 | 683 | 0.010 |
Why?
| | Actins | 1 | 2005 | 383 | 0.010 |
Why?
| | Hearing Loss | 1 | 2006 | 183 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2377 | 0.010 |
Why?
| | Chemokine CCL22 | 1 | 2002 | 3 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2008 | 1147 | 0.010 |
Why?
| | Echocardiography | 1 | 2005 | 558 | 0.010 |
Why?
| | Interphase | 1 | 2001 | 32 | 0.010 |
Why?
| | Palatine Tonsil | 1 | 2001 | 32 | 0.010 |
Why?
| | HL-60 Cells | 1 | 2001 | 27 | 0.010 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 2001 | 21 | 0.010 |
Why?
| | Sinusitis | 1 | 2003 | 175 | 0.010 |
Why?
| | K562 Cells | 1 | 2001 | 73 | 0.010 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2001 | 107 | 0.010 |
Why?
| | Fibroblasts | 1 | 2005 | 839 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2001 | 339 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 2001 | 254 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2009 | 1447 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1987 | 2574 | 0.010 |
Why?
| | Oxazolone | 1 | 1999 | 5 | 0.010 |
Why?
| | Immunomagnetic Separation | 1 | 1999 | 3 | 0.010 |
Why?
| | Ear, External | 1 | 1999 | 23 | 0.010 |
Why?
| | Blood Cells | 1 | 1999 | 38 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2010 | 6417 | 0.010 |
Why?
| | Carbohydrate Metabolism | 1 | 1998 | 50 | 0.010 |
Why?
| | Carbohydrates | 1 | 1998 | 57 | 0.010 |
Why?
| | Endothelium | 1 | 1999 | 115 | 0.010 |
Why?
| | Diffusion Chambers, Culture | 1 | 1997 | 6 | 0.010 |
Why?
| | Chemotactic Factors, Eosinophil | 1 | 1997 | 6 | 0.010 |
Why?
| | Integrin alpha4 | 1 | 1997 | 6 | 0.010 |
Why?
| | Chemokine CCL11 | 1 | 1997 | 22 | 0.010 |
Why?
| | Protein Conformation | 1 | 2000 | 822 | 0.010 |
Why?
| | Antigens, Surface | 1 | 1998 | 151 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2001 | 675 | 0.010 |
Why?
| | Chymotrypsin | 1 | 1996 | 20 | 0.010 |
Why?
| | Time Factors | 1 | 1987 | 6165 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1998 | 1044 | 0.010 |
Why?
| | Chemokine CCL2 | 1 | 1996 | 105 | 0.010 |
Why?
| | Mutation | 1 | 2006 | 3364 | 0.010 |
Why?
| | Carbohydrate Sequence | 1 | 1995 | 23 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1996 | 477 | 0.010 |
Why?
| | Prognosis | 1 | 2002 | 3339 | 0.010 |
Why?
| | Phylogeny | 1 | 1996 | 805 | 0.010 |
Why?
| | Cell Fractionation | 1 | 1989 | 53 | 0.010 |
Why?
| | Lymphokines | 1 | 1989 | 115 | 0.010 |
Why?
| | Culture Media | 1 | 1989 | 156 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 1 | 1989 | 189 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1989 | 244 | 0.010 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1989 | 129 | 0.000 |
Why?
| | Drug Combinations | 1 | 1989 | 289 | 0.000 |
Why?
| | Spleen | 1 | 1989 | 492 | 0.000 |
Why?
| | Hybrid Cells | 1 | 1987 | 49 | 0.000 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1987 | 65 | 0.000 |
Why?
| | Recombination, Genetic | 1 | 1987 | 177 | 0.000 |
Why?
| | Genetic Markers | 1 | 1987 | 325 | 0.000 |
Why?
| | Chromosome Mapping | 1 | 1987 | 489 | 0.000 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1985 | 198 | 0.000 |
Why?
| | Peptides | 1 | 1987 | 864 | 0.000 |
Why?
| | Immunotherapy | 1 | 1985 | 479 | 0.000 |
Why?
| | DNA | 1 | 1987 | 1356 | 0.000 |
Why?
|
|
Fuhlbrigge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|